Welcome to our dedicated page for Y-Mabs Therapeutics news (Ticker: YMAB), a resource for investors and traders seeking the latest updates and insights on Y-Mabs Therapeutics stock.
Y-mAbs Therapeutics, Inc. (YMAB) generates news that spans commercial oncology performance, clinical development milestones in radioimmunotherapy, and significant corporate transactions. Company announcements consistently describe Y-mAbs as a commercial-stage biopharmaceutical company focused on novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, with its lead commercial asset DANYELZA® (naxitamab-gqgk) for relapsed or refractory high-risk neuroblastoma.
News coverage for Y-mAbs frequently highlights financial results and segment updates, including quarterly revenue from DANYELZA, ex-U.S. distribution trends, and the allocation of resources between the DANYELZA and Radiopharmaceuticals business units. Earnings releases often discuss cost of goods sold, research and development spending, selling, general, and administrative expenses, and net loss, along with management commentary on operating strategy and capital efficiency.
Another major category of YMAB news involves clinical and R&D developments in the company’s SADA Pretargeted Radioimmunotherapy (PRIT) platform. Press releases describe progress in the GD2-SADA Phase 1 Trial 1001 in GD2-expressing solid tumors, including pharmacokinetic and dosimetry data, and the initiation of the CD38-SADA Phase 1 Trial 1201 in relapsed or refractory non-Hodgkin lymphoma. Y-mAbs also reports on preclinical pharmacokinetic modeling, optimization of radiohaptens such as “Proteus,” and expansion of its radiopharmaceutical pipeline into additional oncology franchises.
Y-mAbs news also covers regulatory and guideline recognition, such as the inclusion of naxitamab-gqgk (DANYELZA) as a Category 2A treatment option in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma. These updates provide context on how DANYELZA is positioned within clinical practice for high-risk neuroblastoma.
A key theme in recent YMAB headlines is corporate transformation and acquisition activity. In August 2025, Y-mAbs announced that SERB Pharmaceuticals, through an affiliate, agreed to acquire the company in an all-cash transaction at $8.60 per share, with an equity value of approximately $412 million, as described in joint press releases and Form 8-K filings. Subsequent news and SEC filings report the commencement and completion of the tender offer, the closing of the merger, and the resulting delisting of Y-mAbs common stock from the Nasdaq Global Select Market.
Investors and observers following YMAB-related news can expect updates on quarterly financial performance, DANYELZA commercial metrics, clinical trial progress for SADA-based programs, radiopharmaceutical R&D strategy, and the implications of the company’s acquisition by an affiliate of SERB Pharmaceuticals. This news flow provides insight into both the historical public-company phase of Y-mAbs and its transition into a privately held subsidiary within a larger specialty pharmaceutical group.
Y-mAbs Therapeutics (NASDAQ: YMAB) presented preclinical data and trial progress for its CD38-SADA platform at the 2024 ASH Annual Meeting. The preclinical data demonstrated selective binding and anti-tumor efficacy of CD38-SADA when used with Lutetium 177-DOTA in treating Non-Hodgkin Lymphoma (NHL).
The company also presented details of its ongoing Phase 1 Trial 1201, evaluating CD38-SADA PRIT with Lu177-DOTA in adults with relapsed or refractory NHL. The trial consists of two parts: Part A focuses on dose escalation of CD38-SADA protein, while Part B aims to establish the optimal therapeutic dose of Lu177-DOTA. Both parts follow a 3+3 trial design with 4 planned dose levels.
Y-mAbs Therapeutics (Nasdaq: YMAB), a commercial-stage biopharmaceutical company specializing in radioimmunotherapy and antibody-based cancer treatments, has announced its participation in Citi's 2024 Global Healthcare Conference. The company's management team will conduct one-on-one meetings at the conference on December 4, 2024 in Miami, FL. Interested parties can schedule meetings through their Citi representative or by contacting cdu@ymabs.com.
Y-mAbs Therapeutics reported Q3 2024 financial results with total DANYELZA net product revenues of $18.5 million, marking a 10% decline from Q3 2023. The company entered into an exclusive license agreement with Nobelpharma for DANYELZA in Japan, securing a $2.0 million upfront payment. Key developments include the extension of DANYELZA's U.S. patent through February 2034 and market expansion into Turkey. Net loss for Q3 2024 was $7.0 million ($0.16 per share), compared to $7.7 million in Q3 2023. The company maintains its 2024 guidance with expected total net revenues between $87-95 million and cash position supporting operations into 2027.
Y-mAbs Therapeutics (NASDAQ: YMAB) and Nobelpharma have signed an exclusive license and distribution agreement for DANYELZA® in Japan. The agreement covers the development and commercialization of DANYELZA for treating relapsed/refractory high-risk neuroblastoma and potentially relapsed osteosarcoma. Y-mAbs will receive a $2.0 million upfront payment and could earn up to $31.0 million in milestone payments, plus profit sharing on commercial sales. Nobelpharma will handle regulatory submissions, marketing, sales, and distribution in Japan.
Y-mAbs Therapeutics (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on radioimmunotherapy and antibody-based cancer treatments, has scheduled its third quarter 2024 financial results announcement. The company will release results before market open on November 8, 2024, followed by a conference call and webcast at 8:00 a.m. ET. Domestic investors can dial (877) 407-0792, while international investors can use (201) 689-8263 to participate.
Y-mAbs Therapeutics (Nasdaq: YMAB), a commercial-stage biopharmaceutical company specializing in novel radioimmunotherapy and antibody-based therapeutic products for cancer treatment, has announced its participation in two upcoming investor conferences in October 2024:
1. Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit:
- Date: Tuesday, October 8, 2024
- Time: 9:30 a.m. ET
- Location: New York, NY
- Panel: "The Next Wave of TRTs – Targets, Targeting Technologies and Isotopes"
2. BMO Oncology Summit:
- Date: Tuesday, October 8, 2024
- Time: 3:00 p.m. ET
- Location: New York, NY
- Fireside chat: "Shifting the Antibody Paradigm"
These conferences provide Y-mAbs with opportunities to showcase its developments in cancer therapeutics and engage with investors.
Y-mAbs Therapeutics (Nasdaq: YMAB) presented new clinical and preclinical data on naxitamab and GD2-SADA for neuroblastoma treatment at the AACR Special Conference. Key findings include:
1. Naxitamab with GM-CSF achieved a 63% disease control rate in refractory/relapsed high-risk neuroblastoma patients.
2. GD2-SADA demonstrated high-affinity binding to Tb-DOTA, supporting its potential in pre-targeted radiotherapy (PRIT).
3. Ongoing clinical trials: Trial 201 for naxitamab, Trial 1001 for GD2-SADA PRIT in adolescents and adults, and planned Trial 1002 for pediatric patients.
These results highlight Y-mAbs' progress in developing innovative treatments for high-risk neuroblastoma, the most common extracranial solid tumor in children.
Y-mAbs Therapeutics (Nasdaq: YMAB), a commercial-stage biopharmaceutical company specializing in novel radioimmunotherapy and antibody-based therapeutic products for cancer treatment, has announced its participation in two upcoming investor conferences. Michael Rossi, President and CEO, will represent the company at:
1. Morgan Stanley 22nd Annual Global Healthcare Conference on September 6, 2024, at 1:50 p.m. ET in New York, NY.
2. Cantor Global Healthcare Conference on September 17, 2024, at 3:40 p.m. ET in New York, NY.
Both events will feature fireside chats and investor 1x1 meetings. Live webcasts of the fireside chats and related materials will be available on Y-mAbs' investor relations website under the Presentations section, with archives accessible for at least 30 days.
Y-mAbs Therapeutics (YMAB) reported Q2 2024 financial results and corporate developments. Highlights include:
- DANYELZA net product revenues of $22.8 million, up 10% YoY
- Geographic expansion with new revenues from Brazil and Mexico
- Phase 1 GD2-SADA Trial Part A expected completion in Q4 2024
- Appointed new CFO and Chief Development Officer
- Cash and cash equivalents of $77.8 million as of June 30, 2024
- Updated Full Year 2024 Total Net Revenue guidance
The company reported a net loss of $9.2 million ($0.21 per share) for Q2 2024, compared to a $6.3 million loss ($0.14 per share) in Q2 2023. Management expects current cash to support operations into 2027.
Y-mAbs Therapeutics (Nasdaq: YMAB), a commercial-stage biopharmaceutical company specializing in novel radioimmunotherapy and antibody-based cancer treatments, has announced its participation in two upcoming investor conferences in August 2024:
1. Wedbush PacGrow Healthcare Conference on August 13 in New York, NY, featuring investor 1x1 meetings.
2. Canaccord Genuity 44th Annual Growth Conference on August 14 in Boston, MA, including a fireside chat at 8:00 a.m. ET and investor 1x1 meetings.
A live webcast of Y-mAbs' fireside chat and related materials will be available on the company's investor relations website. The webcast will be archived for at least 30 days.